



2-1250 Waverley Street  
Winnipeg, Manitoba, Canada R3T 6C6  
Phone: 204-487-7412  
Fax: 204-488-9823

## **Medicure Announces Upcoming Conference Presentations**

**WINNIPEG, April 5, 2016** - Medicure Inc. ("**Medicure**") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will be participating and presenting at the following investor conferences in April and May, 2016;

- April 7<sup>th</sup> at the Laurentian Bank Securities Annual Institutional Investor Conference at the Sofitel Hotel, Montreal. Medicure's CEO and Chairman, Albert Friesen, will participate in a healthcare panel entitled "Specialty Pharmaceuticals - Continuing Success in Challenging Markets". The panel runs 1:35 PM – 3:00 PM.
- April 11<sup>th</sup> - 12<sup>th</sup> at The MicroCap Conference at the Hilton Toronto. Medicure's President and COO, Dawson Reimer, will present a corporate update at 2:30 PM on April 12<sup>th</sup>.
- May 2<sup>nd</sup> – 3<sup>rd</sup> at the Bloom Burton & Co Healthcare Investor Conference at the Sheraton Centre Toronto Hotel. Medicure's President and COO, Dawson Reimer, will present a corporate update at 11:30 AM on May 3<sup>rd</sup>.

### **About Medicure Inc.**

Medicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market. The primary focus of the Company and its subsidiaries is the marketing and distribution of AGGRASTAT (tirofiban HCl) for non-ST elevation acute coronary syndrome in the United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc. For more information on Medicure please visit [www.medicure.com](http://www.medicure.com).